Mike khan

Mike khan


Job title: CEO


Developing the Next-Generation of Single & Dual Targeting siRNAs, Using DNA Nanotechnology 3:00 pm

As an alternative to standard 2’ chemical modification, we will discuss how DNA nanotechnology can be employed to confer critical therapeutic properties on siRNAs These properties include tolerability and efficacy via stability to nuclease degradation and serum protein binding Further important platform advantages of DNA-RNA hybrid agents include the potential for the short duration of…Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.